SCHEMBL13615812

SCHEMBL13615812

c1ccc(N(c2ccccc2)c2ccc(-c3c4ccc(N(c5ccccc5)c5ccccc5)cc4c(-c4ccc(N(c5ccccc5)c5ccccc5)cc4)c4cc(N(c5ccccc5)c5ccccc5)ccc34)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2D6 P10635 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPT P10636 1/20 0.43
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
CRHBP P24387 1/20 0.37
ATM Q13315 1/20 0.37
CRHR2 Q13324 1/20 0.37
TLR9 Q9NR96 1/20 0.37
ACHE P22303 3/20 0.37
APP P05067 1/20 0.36
ESR1 P03372 3/20 0.31
ESR2 Q92731 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12337526 1.00 ALDH1A1 (0.43) ALDH1A1L3MBTL1TDP1CYP1A2CYP3A4
SCHEMBL13304054 0.98 ALDH1A1 (0.42) ALDH1A1L3MBTL1TDP1CYP1A2CYP3A4
SCHEMBL13304292 0.98 ALDH1A1 (0.42) ALDH1A1L3MBTL1TDP1CYP1A2CYP3A4
SCHEMBL12928332 0.96 ALDH1A1 (0.41) ALDH1A1L3MBTL1TDP1CYP1A2CYP3A4
SCHEMBL14099683 0.96 ALDH1A1 (0.41) ALDH1A1L3MBTL1TDP1CYP1A2CYP3A4
SCHEMBL12770707 0.96 ALDH1A1 (0.41) ALDH1A1L3MBTL1TDP1CYP1A2CYP3A4
SCHEMBL13615742 0.96 ALDH1A1 (0.41) ALDH1A1L3MBTL1TDP1CYP1A2CYP3A4
SCHEMBL13615687 0.96 ALDH1A1 (0.41) ALDH1A1L3MBTL1TDP1CYP1A2CYP3A4
SCHEMBL12337529 0.96 ALDH1A1 (0.41) ALDH1A1L3MBTL1TDP1CYP1A2CYP3A4
SCHEMBL10304788 0.96 ALDH1A1 (0.41) ALDH1A1L3MBTL1TDP1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090273277-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-11-05 US disclosed
US-20090273277-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-11-05 US disclosed
EP-2103666-A2 Novel organic electroluminescent compounds and organic electroluminescent device using the same Gracel Display Inc. (KR) 2009-09-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090273277-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same OCIAD1, ORMDL3, CHRM2 ALDH1A1 818/4885L3MBTL1 283/4885TDP1 3634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.